# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in ...
Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and lowers the price target from $...
ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval
The QUILT 502 trial is testing ImmunityBio's N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for ...